{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:46:31Z","timestamp":1794854791560,"version":"4.9.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["1R44NS115426, 1R44NS137943"],"award-info":[{"award-number":["1R44NS115426, 1R44NS137943"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["1R44NS115426"],"award-info":[{"award-number":["1R44NS115426"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["1R44NS137943"],"award-info":[{"award-number":["1R44NS137943"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031160","name":"Cartesian Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031160","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Cartesian Therapeutics (Note: these three funding sources"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41591-025-04170-z","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:01:42Z","timestamp":1767963702000},"page":"1118-1130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4284-9283","authenticated-orcid":false,"given":"Renee R.","family":"Fedak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2578-3028","authenticated-orcid":false,"given":"Rachel N.","family":"Ruggerie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Curvino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana F.","family":"de Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhtran","family":"Ngo-Casi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafsa","family":"Kamboh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0724-0210","authenticated-orcid":false,"given":"Tuan","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hacer","family":"Durmu\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahseen","family":"Mozaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-8617","authenticated-orcid":false,"suffix":"Jr.","given":"James F.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1621-4669","authenticated-orcid":false,"given":"Emily P.","family":"English","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albina","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Duvernay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat V.","family":"Kalayoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Brunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8943-8233","authenticated-orcid":false,"given":"Aaron","family":"Bodansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3093-4758","authenticated-orcid":false,"given":"Mark S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"DeRisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha T.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J. L.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1227-2137","authenticated-orcid":false,"given":"Kelsey C.","family":"Zorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metin","family":"Kurtoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo\u0161 D.","family":"Miljkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7936-447X","authenticated-orcid":false,"given":"C. Andrew","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6668-6928","authenticated-orcid":false,"given":"Christopher M.","family":"Jewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the MG-001 Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana F.","family":"de Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charito","family":"Buensuceso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa H.","family":"Tostanoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad A.","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"English","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atanas","family":"Filev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Biaksangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rivner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Badruddoja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bennett","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheetal","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Slanksy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Holley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Sahagian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Quesnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc H.","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"DeMaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithila","family":"Vullaganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Barnett-Tapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Irannejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaeem","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ragole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamatha","family":"Pasnoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca E.","family":"Traub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara A.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Karafin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Trunnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chafic","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darnell","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naraly","family":"Requena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Peltier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Gwathmey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"4170_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018.","journal-title":"N. Engl. J. Med."},{"key":"4170_CR2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado2084","volume":"16","author":"EP English","year":"2024","unstructured":"English, E. P. et al. Engineering CAR-T therapies for autoimmune disease and beyond. Sci. Transl. Med. 16, eado2084 (2024).","journal-title":"Sci. Transl. Med."},{"key":"4170_CR3","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit, V. et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study. Lancet Neurol. 22, 578\u2013590 (2023).","journal-title":"Lancet Neurol."},{"key":"4170_CR4","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1002\/acn3.70167","volume":"12","author":"N Chahin","year":"2025","unstructured":"Chahin, N. et al. Durability of response to B\u2011cell maturation antigen\u2011directed mRNA cell therapy in myasthenia gravis. Ann. Clin. Transl. Neurol. 12, 2358\u20132366 (2025).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"4170_CR5","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/s41375-020-0951-5","volume":"35","author":"L Lin","year":"2021","unstructured":"Lin, L. et al. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia 35, 752\u2013763 (2021).","journal-title":"Leukemia"},{"key":"4170_CR6","doi-asserted-by":"publisher","unstructured":"Vu, T. et al. BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-025-04171-y (2026).","DOI":"10.1038\/s41591-025-04171-y"},{"key":"4170_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01193-6","volume":"14","author":"Z Tao","year":"2024","unstructured":"Tao, Z. et al. Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies. Blood Cancer J. 14, 213 (2024).","journal-title":"Blood Cancer J."},{"key":"4170_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nm.4241","volume":"23","author":"L Gattinoni","year":"2017","unstructured":"Gattinoni, L., Speiser, D. E., Lichterfeld, M. & Bonini, C. T memory stem cells in health and disease. Nat. Med. 23, 18\u201327 (2017).","journal-title":"Nat. Med."},{"key":"4170_CR9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2308511120","volume":"120","author":"R Sender","year":"2023","unstructured":"Sender, R. et al. The total mass, number, and distribution of immune cells in the human body. Proc. Natl Acad. Sci. USA 120, e2308511120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4170_CR10","doi-asserted-by":"publisher","first-page":"8209737","DOI":"10.1155\/2020\/8209737","volume":"2020","author":"E Elm\u00e9r","year":"2020","unstructured":"Elm\u00e9r, E. et al. Increased frequencies of switched memory B cells and plasmablasts in peripheral blood from patients with ANCA-associated vasculitis. J. Immunol. Res. 2020, 8209737 (2020).","journal-title":"J. Immunol. Res."},{"key":"4170_CR11","doi-asserted-by":"publisher","first-page":"e1139","DOI":"10.1002\/cti2.1139","volume":"9","author":"Y Ye","year":"2020","unstructured":"Ye, Y., Gaugler, B., Mohty, M. & Malard, F. Plasmacytoid dendritic cell biology and its role in immune-mediated diseases. Clin. Transl. Immunol. 9, e1139 (2020).","journal-title":"Clin. Transl. Immunol."},{"key":"4170_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O\u2019Connor","year":"2004","unstructured":"O\u2019Connor, B. P. et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199, 91\u201398 (2004).","journal-title":"J. Exp. Med."},{"key":"4170_CR13","doi-asserted-by":"publisher","unstructured":"Bodansky, A. et al. Unveiling the autoreactome: proteome-wide immunological fingerprints reveal the promise of plasma cell depleting therapy. Preprint at medRxiv https:\/\/doi.org\/10.1101\/2023.12.19.23300188 (2023).","DOI":"10.1101\/2023.12.19.23300188"},{"key":"4170_CR14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI180012","volume":"134","author":"A Bodansky","year":"2024","unstructured":"Bodansky, A. et al. Unveiling the proteome-wide autoreactome enables enhanced evaluation of emerging CAR T cell therapies in autoimmunity. J. Clin. Invest. 134, e180012 (2024).","journal-title":"J. Clin. Invest."},{"key":"4170_CR15","doi-asserted-by":"publisher","first-page":"596981","DOI":"10.3389\/fneur.2020.596981","volume":"11","author":"K Lazaridis","year":"2020","unstructured":"Lazaridis, K. & Tzartos, S. J. Myasthenia gravis: autoantibody specificities and their role in MG management. Front. Neurol. 11, 596981 (2020).","journal-title":"Front. Neurol."},{"key":"4170_CR16","doi-asserted-by":"publisher","first-page":"577634","DOI":"10.1016\/j.jneuroim.2021.577634","volume":"358","author":"A Uzawa","year":"2021","unstructured":"Uzawa, A. et al. High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis. J. Neuroimmunol. 358, 577634 (2021).","journal-title":"J. Neuroimmunol."},{"key":"4170_CR17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrrheum.2018.31","volume":"14","author":"TLW Muskardin","year":"2018","unstructured":"Muskardin, T. L. W. & Niewold, T. B. Type I interferon in rheumatic diseases. Nat. Rev. Rheumatol. 14, 214\u2013228 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"4170_CR18","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3389\/fimmu.2019.00721","volume":"10","author":"L Khodadadi","year":"2019","unstructured":"Khodadadi, L., Cheng, Q., Radbruch, A. & Hiepe, F. The maintenance of memory plasma cells. Front. Immunol. 10, 721 (2019).","journal-title":"Front. Immunol."},{"key":"4170_CR19","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.4049\/jimmunol.171.4.1684","volume":"171","author":"G Cassese","year":"2003","unstructured":"Cassese, G. et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J. Immunol. 171, 1684\u20131690 (2003).","journal-title":"J. Immunol."},{"key":"4170_CR20","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3390\/ijms23020627","volume":"23","author":"Y Zhong","year":"2022","unstructured":"Zhong, Y., Zhang, X. & Chong, W. Interleukin-24 immunobiology and its roles in inflammatory diseases. Int. J. Mol. Sci. 23, 627 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"4170_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030491","volume":"3","author":"JW Bauer","year":"2006","unstructured":"Bauer, J. W. et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 3, e491 (2006).","journal-title":"PLoS Med."},{"key":"4170_CR22","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s12013-024-01576-3","volume":"83","author":"Q An","year":"2024","unstructured":"An, Q., Gu, X. & Jiang, Y. The role of interleukin-24 and downstream pathways in inflammatory and autoimmune diseases. Cell Biochem. Biophys. 83, 1333\u20131345 (2024).","journal-title":"Cell Biochem. Biophys."},{"key":"4170_CR23","doi-asserted-by":"publisher","first-page":"1443363","DOI":"10.3389\/fimmu.2024.1443363","volume":"15","author":"S Elahi","year":"2024","unstructured":"Elahi, S., Rezaeifar, M., Osman, M. & Shahbaz, S. Exploring the role of galectin-9 and artemin as biomarkers in long COVID with chronic fatigue syndrome: links to inflammation and cognitive function. Front. Immunol. 15, 1443363 (2024).","journal-title":"Front. Immunol."},{"key":"4170_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2003.08.021","volume":"171","author":"T Hasegawa","year":"2003","unstructured":"Hasegawa, T. et al. The regulation of EN-RAGE (S100A12) gene expression in human THP-1 macrophages. Atherosclerosis 171, 211\u2013218 (2003).","journal-title":"Atherosclerosis"},{"key":"4170_CR25","doi-asserted-by":"publisher","first-page":"103920","DOI":"10.1016\/j.autrev.2025.103920","volume":"24","author":"X Wang","year":"2025","unstructured":"Wang, X., Luo, Y., Zhou, Q. & Ma, J. The roles of S100A8\/A9 and S100A12 in autoimmune diseases: mechanisms, biomarkers, and therapeutic potential. Autoimmun. Rev. 24, 103920 (2025).","journal-title":"Autoimmun. Rev."},{"key":"4170_CR26","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41573-024-01053-9","volume":"23","author":"M Croft","year":"2024","unstructured":"Croft, M., Salek-Ardakani, S. & Ware, C. F. Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer. Nat. Rev. Drug Discov. 23, 939\u2013961 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4170_CR27","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1172\/JCI200113827","volume":"108","author":"J Wang","year":"2001","unstructured":"Wang, J. et al. The regulation of T cell homeostasis and autoimmunity by T cell\u2013derived LIGHT. J. Clin. Invest. 108, 1771\u20131780 (2001).","journal-title":"J. Clin. Invest."},{"key":"4170_CR28","doi-asserted-by":"crossref","unstructured":"Mantel, P.-Y. & Schmidt-Weber, C. B. Transforming growth factor-beta: recent advances on its role in immune tolerance. in Suppression and Regulation of Immune Responses (eds Cuturi, M. C. & Anegon, I.) 677, 303\u2013338 (Humana Press, 2010).","DOI":"10.1007\/978-1-60761-869-0_21"},{"key":"4170_CR29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev.immunol.24.021605.090737","volume":"24","author":"MO Li","year":"2006","unstructured":"Li, M. O., Wan, Y. Y., Sanjabi, S., Robertson, A.-K. L. & Flavell, R. A. Transforming growth factor-\u03b2 regulation of immune responses. Annu. Rev. Immunol. 24, 99\u2013146 (2006).","journal-title":"Annu. Rev. Immunol."},{"key":"4170_CR30","doi-asserted-by":"publisher","first-page":"e33713","DOI":"10.1371\/journal.pone.0033713","volume":"7","author":"T Anjubault","year":"2012","unstructured":"Anjubault, T. et al. Constitutive expression of TNF-related activation-induced cytokine (TRANCE)\/receptor activating NF-\u03baB ligand (RANK)-L by rat plasmacytoid dendritic cells. PLoS ONE 7, e33713 (2012).","journal-title":"PLoS ONE"},{"key":"4170_CR31","doi-asserted-by":"publisher","first-page":"674343","DOI":"10.3389\/fimmu.2021.674343","volume":"12","author":"H Zhan","year":"2021","unstructured":"Zhan, H. et al. Association of circulating vascular endothelial growth factor levels with autoimmune diseases: a systematic review and meta-analysis. Front. Immunol. 12, 674343 (2021).","journal-title":"Front. Immunol."},{"key":"4170_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-017-0892-8","volume":"14","author":"KM Danikowski","year":"2017","unstructured":"Danikowski, K. M., Jayaraman, S. & Prabhakar, B. S. Regulatory T cells in multiple sclerosis and myasthenia gravis. J. Neuroinflammation 14, 117 (2017).","journal-title":"J. Neuroinflammation"},{"key":"4170_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.it.2006.02.008","volume":"27","author":"KJ Wood","year":"2006","unstructured":"Wood, K. J. & Sawitzki, B. Interferon \u03b3: a crucial role in the function of induced regulatory T cells in vivo. Trends Immunol. 27, 183\u2013187 (2006).","journal-title":"Trends Immunol."},{"key":"4170_CR34","doi-asserted-by":"publisher","first-page":"595","DOI":"10.4049\/jimmunol.2200053","volume":"210","author":"T Aaron","year":"2023","unstructured":"Aaron, T. et al. TNF-\u03b1 limits serological memory by disrupting the bone marrow niche. J. Immunol. 210, 595\u2013608 (2023).","journal-title":"J. Immunol."},{"key":"4170_CR35","doi-asserted-by":"publisher","first-page":"785","DOI":"10.4049\/jimmunol.1901358","volume":"206","author":"A Psarras","year":"2021","unstructured":"Psarras, A. et al. TNF-\u03b1 regulates human plasmacytoid dendritic cells by suppressing IFN-\u03b1 production and enhancing T cell activation. J. Immunol. 206, 785\u2013796 (2021).","journal-title":"J. Immunol."},{"key":"4170_CR36","doi-asserted-by":"publisher","first-page":"a001651","DOI":"10.1101\/cshperspect.a001651","volume":"1","author":"T Lawrence","year":"2009","unstructured":"Lawrence, T. The nuclear factor NF-\u03baB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 1, a001651 (2009).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"4170_CR37","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.4049\/jimmunol.1202317","volume":"189","author":"O Winter","year":"2012","unstructured":"Winter, O., Dame, C., Jundt, F. & Hiepe, F. Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy. J. Immunol. 189, 5105\u20135111 (2012).","journal-title":"J. Immunol."},{"key":"4170_CR38","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41577-025-01141-w","volume":"25","author":"T Junt","year":"2025","unstructured":"Junt, T. et al. Defining immune reset: achieving sustained remission in autoimmune diseases. Nat. Rev. Immunol. 25, 528\u2013541 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"4170_CR39","doi-asserted-by":"publisher","first-page":"10845","DOI":"10.3390\/ijms251910845","volume":"25","author":"J Martin","year":"2024","unstructured":"Martin, J. et al. B-cell maturation antigen (BCMA) as a biomarker and potential treatment target in systemic lupus erythematosus. Int. J. Mol. Sci. 25, 10845 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"4170_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-63390-0","volume":"10","author":"DC Salazar-Camarena","year":"2020","unstructured":"Salazar-Camarena, D. C., Palafox-S\u00e1nchez, C. A., Cruz, A., Mar\u00edn-Rosales, M. & Mu\u00f1oz-Valle, J. F. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients. Sci. Rep. 10, 6236 (2020).","journal-title":"Sci. Rep."},{"key":"4170_CR41","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.4049\/jimmunol.1601746","volume":"198","author":"E Schuh","year":"2017","unstructured":"Schuh, E. et al. Human plasmacytoid dendritic cells display and shed b cell maturation antigen upon TLR engagement. J. Immunol. 198, 3081\u20133088 (2017).","journal-title":"J. Immunol."},{"key":"4170_CR42","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1212\/WNL.35.4.577","volume":"35","author":"Y Fujii","year":"1985","unstructured":"Fujii, Y., Monden, Y., Hashimoto, J., Nakahara, K. & Kawashima, Y. Acetylcholine receptor antibody production by bone marrow cells in a patient with myasthenia gravis. Neurology 35, 577\u2013579 (1985).","journal-title":"Neurology"},{"key":"4170_CR43","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.4049\/jimmunol.167.4.1935","volume":"167","author":"GP Sims","year":"2001","unstructured":"Sims, G. P., Shiono, H., Willcox, N. & Stott, D. I. Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis. J. Immunol. 167, 1935\u20131944 (2001).","journal-title":"J. Immunol."},{"key":"4170_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110564","volume":"27","author":"AK Bhandage","year":"2024","unstructured":"Bhandage, A. K. et al. Serum protein biomarker profile distinguishes acetylcholine receptor antibody seropositive myasthenia gravis patients from healthy controls. iScience 27, 110564 (2024).","journal-title":"iScience"},{"key":"4170_CR45","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","volume":"20","author":"G Schett","year":"2024","unstructured":"Schett, G. et al. Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat. Rev. Rheumatol. 20, 531\u2013544 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"4170_CR46","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/j.immuni.2024.10.011","volume":"57","author":"G Schett","year":"2024","unstructured":"Schett, G. & June, C. H. CAR T cells in autoimmune disease: on the road to remission. Immunity 57, 2705\u20132709 (2024).","journal-title":"Immunity"},{"key":"4170_CR47","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"4170_CR48","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts, P. et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J. Clin. Invest. 128, 4372\u20134386 (2018).","journal-title":"J. Clin. Invest."},{"key":"4170_CR49","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard","year":"2021","unstructured":"Howard, J. F. et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 20, 526\u2013536 (2021).","journal-title":"Lancet Neurol."},{"key":"4170_CR50","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s40120-023-00514-4","volume":"12","author":"T Vu","year":"2023","unstructured":"Vu, T. et al. Summary of research: terminal complement inhibitor ravulizumab in generalized myasthenia gravis. Neurol. Ther. 12, 1435\u20131438 (2023).","journal-title":"Neurol. Ther."},{"key":"4170_CR51","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","volume":"22","author":"A Haghikia","year":"2023","unstructured":"Haghikia, A. et al. Anti-CD19 CAR T cells for refractory myasthenia gravis. Lancet Neurol. 22, 1104\u20131105 (2023).","journal-title":"Lancet Neurol."},{"key":"4170_CR52","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1136\/ard-2024-226017","volume":"83","author":"A Haghikia","year":"2024","unstructured":"Haghikia, A. et al. Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis. Ann. Rheum. Dis. 83, 1597\u20131598 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"4170_CR53","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/ene.15238","volume":"29","author":"F Marcuse","year":"2022","unstructured":"Marcuse, F. et al. The association between anti-acetylcholine receptor antibody level and clinical improvement in myasthenia gravis. Eur. J. Neurol. 29, 1187\u20131197 (2022).","journal-title":"Eur. J. Neurol."},{"key":"4170_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2203","volume":"11","author":"L Wang","year":"2021","unstructured":"Wang, L. et al. No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: a systematic retrospective study involving 67 patients. Brain Behav. 11, e02203 (2021).","journal-title":"Brain Behav."},{"key":"4170_CR55","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.expneurol.2015.01.011","volume":"270","author":"PM Rodriguez Cruz","year":"2015","unstructured":"Rodriguez Cruz, P. M., Huda, S., L\u00f3pez-Ruiz, P. & Vincent, A. Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases. Exp. Neurol. 270, 66\u201371 (2015).","journal-title":"Exp. Neurol."},{"key":"4170_CR56","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00401-023-02603-y","volume":"146","author":"MC Pham","year":"2023","unstructured":"Pham, M. C. et al. Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathol. 146, 319\u2013336 (2023).","journal-title":"Acta Neuropathol."},{"key":"4170_CR57","doi-asserted-by":"publisher","first-page":"e200436","DOI":"10.1212\/NXI.0000000000200436","volume":"12","author":"F Khani-Habibabadi","year":"2025","unstructured":"Khani-Habibabadi, F. et al. AChR autoantibody pathogenic properties are heterogeneously distributed and undergo temporal changes among patients with myasthenia gravis. Neurol. Neuroimmunol. Neuroinflamm. 12, e200436 (2025).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"4170_CR58","doi-asserted-by":"publisher","first-page":"686466","DOI":"10.3389\/fimmu.2021.686466","volume":"12","author":"C Zografou","year":"2021","unstructured":"Zografou, C., Vakrakou, A. G. & Stathopoulos, P. Short- and long-lived autoantibody-secreting cells in autoimmune neurological disorders. Front. Immunol. 12, 686466 (2021).","journal-title":"Front. Immunol."},{"key":"4170_CR59","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.165373","volume":"8","author":"SS Yandamuri","year":"2023","unstructured":"Yandamuri, S. S. et al. MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity. JCI Insight 8, e165373 (2023).","journal-title":"JCI Insight"},{"key":"4170_CR60","doi-asserted-by":"publisher","unstructured":"Stewart, C. A. et al. mRNA engineering of allogeneic mesenchymal stem cells enables coordinated delivery of T cell engagers and immunotherapeutic cues. Nat. Biomed. Eng. https:\/\/doi.org\/10.1038\/s41551-025-01552-z (2025).","DOI":"10.1038\/s41551-025-01552-z"},{"key":"4170_CR61","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1182\/blood-2009-07-235960","volume":"114","author":"M Jourdan","year":"2009","unstructured":"Jourdan, M. et al. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood 114, 5173\u20135181 (2009).","journal-title":"Blood"},{"key":"4170_CR62","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1038\/leu.2014.61","volume":"28","author":"M Jourdan","year":"2014","unstructured":"Jourdan, M. et al. IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors. Leukemia 28, 1647\u20131656 (2014).","journal-title":"Leukemia"},{"key":"4170_CR63","doi-asserted-by":"publisher","unstructured":"Bodansky, A. et al. A distinct cross-reactive autoimmune response in multisystem inflammatory syndrome in children (MIS-C). Preprint at medRxiv https:\/\/doi.org\/10.1101\/2023.05.26.23290373 (2023).","DOI":"10.1101\/2023.05.26.23290373"},{"key":"4170_CR64","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 42, 293\u2013304 (2024).","journal-title":"Nat. Biotechnol."},{"key":"4170_CR65","doi-asserted-by":"publisher","first-page":"giaa151","DOI":"10.1093\/gigascience\/giaa151","volume":"9","author":"MD Young","year":"2020","unstructured":"Young, M. D. & Behjati, S. SoupX removes ambient RNA contamination from droplet-based single-cell RNA sequencing data. GigaScience 9, giaa151 (2020).","journal-title":"GigaScience"},{"key":"4170_CR66","doi-asserted-by":"publisher","first-page":"979","DOI":"10.12688\/f1000research.73600.2","volume":"10","author":"P-L Germain","year":"2022","unstructured":"Germain, P.-L., Lun, A., Garcia Meixide, C., Macnair, W. & Robinson, M. D. Doublet identification in single-cell sequencing data using scDblFinder. F1000Res. 10, 979 (2022).","journal-title":"F1000Res."},{"key":"4170_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1874-1","volume":"20","author":"C Hafemeister","year":"2019","unstructured":"Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 20, 296 (2019).","journal-title":"Genome Biol."},{"key":"4170_CR68","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"4170_CR69","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 (2021).","journal-title":"Cell"},{"key":"4170_CR70","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2016","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2016).","journal-title":"Genome Biol."},{"key":"4170_CR71","doi-asserted-by":"publisher","unstructured":"Korotkevich, G. et al. Fast gene set enrichment analysis. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/060012 (2021).","DOI":"10.1101\/060012"},{"key":"4170_CR72","doi-asserted-by":"publisher","first-page":"e2203828120","DOI":"10.1073\/pnas.2203828120","volume":"120","author":"S Mangiola","year":"2023","unstructured":"Mangiola, S.et al.sccomp: robust differential composition and variability analysis for single-cell data. Proc. Natl Acad. Sci. USA 120, e2203828120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4170_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3680","volume":"4","author":"CS Carlson","year":"2013","unstructured":"Carlson, C. S. et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat. Commun. 4, 2680 (2013).","journal-title":"Nat. Commun."},{"key":"4170_CR74","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jim.2011.09.001","volume":"375","author":"H Robins","year":"2012","unstructured":"Robins, H. et al. Ultra-sensitive detection of rare T cell clones. J. Immunol. Methods 375, 14\u201319 (2012).","journal-title":"J. Immunol. Methods"},{"key":"4170_CR75","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2009-04-217604","volume":"114","author":"HS Robins","year":"2009","unstructured":"Robins, H. S. et al. Comprehensive assessment of T-cell receptor \u03b2-chain diversity in \u03b1\u03b2 T cells. Blood 114, 4099\u20134107 (2009).","journal-title":"Blood"},{"key":"4170_CR76","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1128\/JVI.03474-14","volume":"89","author":"WS DeWitt","year":"2015","unstructured":"DeWitt, W. S. et al. Dynamics of the cytotoxic T cell response to a model of acute viral infection. J. Virol. 89, 4517\u20134526 (2015).","journal-title":"J. Virol."},{"key":"4170_CR77","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1214\/08-AOAS194","volume":"3","author":"Y Benjamini","year":"2009","unstructured":"Benjamini, Y. & Gavrilov, Y. A simple forward selection procedure based on false discovery rate control. Ann. Appl. Stat. 3, 179\u2013198 (2009).","journal-title":"Ann. Appl. Stat."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04170-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04170-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04170-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:02:34Z","timestamp":1774018954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04170-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4170"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04170-z","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.R.F., R.N.R., Y.S., E.J.C., J.F.S., S.D., M.N.-C., H.K., E.P.E., A. Benson, M.T.D., C. Buensuceso, C. Brunn, M.S.S., M.V.K., M. Kurtoglu, M.D.M., C.A.S. and C.M.J. are employees of and\/or hold equity in Cartesian Therapeutics. C.M.J. is appointed as a Professor at the University of Maryland and a Research Health Scientist at the VA Maryland Health Care System. The views in this paper do not reflect the views of the State of Maryland or the US government. C.M.J. is founder of Nodal Therapeutics and Patch Bio and holds equity positions with Nodal Therapeutics, Patch Bio, Aletira Therapeutics and Barinthus Biotherapeutics. C.B.-T. has served as member of the advisory board for argenx, Alexion, UCB, Janssen and NMD Pharma. She has been a consultant for argenx, Janssen, Novartis and UCB. She has received research support from US Department of Defense, Muscular Dystrophy Canada and MGNet. She is the primary developer of the MGII and may receive royalties. T.V. is a site principal investigator at the University of South Florida for myasthenia gravis clinical trials sponsored by Alexion\/AstraZeneca, argenx, Amgen, Cartesians, COUR, Dianthus, EMD Serono, Johnson & Johnson, Immunovant, NMD Pharma, Regeneron and UCB. T.V. received speaking and\/or consulting honoraria related to myasthenia gravis from Alexion, Amgen, argenx, Dianthus and Johnson & Johnson. T.M. has received research funding from the Muscular Dystrophy Association and the National Institutes of Health (R01AR074457, UM1TR004927, R21AR082649, UO1NS139215 and T32AR083870). T.M. has received research funding from the following sponsors: Alexion, Amicus, AnnJi, argenx, Aro Bio, Ask Bio, Audients (now Astellas Gene Therapy), Cabaletta, Cartesian Therapeutics, Fate Therapeutics, ML-Bio, Momenta, NKarta, Ra Pharmaceuticals, Sanofi, Spark Therapeutics and Valerion. T.M. has served as a consultant for Alexion, Amicus, AnnJi, argenx, Aro Bio, Arvinas, Ask Bio, Astellas Gene Therapeutics, AvroBio, BioCryst, Cabaletta, Creyon, Dyne, Fate Therapeutics, Horizon Therapeutics, Immunovant, Maze Therapeutics, Merck, Poseida, Regeneron, Shionogi, Momenta (now Janssen), Sanofi, UCB and Variant Bio. T.M. serves on the medical advisory board for the Myositis Association and the Neuromuscular Disease Foundation. He serves on the data safety monitoring board for Acceleron, Applied Therapeutics (Chair), Avidity, Sarepta, Sirolimus in IBM trial (Chair) and the NI. J.F.H. disclosures include research funding (paid to his institution) from Ad Scientiam, Alexion AstraZeneca Rare Disease, argenx, Cartesian Therapeutics, Centers for Disease Control and Prevention, Merck EMD Serono, MGFA, Muscular Dystrophy Association, NIH, NMD Pharma and UCB Bioscience; honoraria\/consulting fees from AcademicCME, Alexion AstraZeneca Rare Disease, Amgen, argenx, Biohaven Ltd, Cartesian Therapeutics, CheckRare CME, CorEvitas, Curie.Bio, H. Lundbeck A\/S, Japan Tobacco Company, Merck EMB Serono, NMD Pharma, Novartis Pharma, PeerView CME, Physicians\u2032 Education Resource (PER) CME, PlatformQ CME, Regeneron Pharmaceuticals, Seismic Therapeutics, TG Therapeutics, Toleranzia AB and UCB Pharma. H.D. has served as a speaker and consultant for Alexion\/AstraZeneca and UCB. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}